Home » Changes in hemoglobin measures observed in PNH patients treated with both c5 inhibitors ravulizumab and eculizumab: real-world evidence from a US-Based EMR network
Changes in hemoglobin measures observed in PNH patients treated with both c5 inhibitors ravulizumab and eculizumab: real-world evidence from a US-Based EMR network - TriNetX
Changes in hemoglobin measures observed in PNH patients treated with both c5 inhibitors ravulizumab and eculizumab: real-world evidence from a US-Based EMR network
